CA3212151A1 — Treatment and/or reduction of occurrence of migraine
Assigned to Cgrp Diagnostics GmbH · Expires 2022-09-09 · 4y expired
What this patent protects
There is described a method of treating migraine in certain subjects suffering from migraine, by administration of a gepant to the subject. Also described is a method of reducing the incidence of migraine in certain subjects suffering from migraine, by administration of a gepant …
USPTO Abstract
There is described a method of treating migraine in certain subjects suffering from migraine, by administration of a gepant to the subject. Also described is a method of reducing the incidence of migraine in certain subjects suffering from migraine, by administration of a gepant to the subject. Also described are methods for identifying the certain subjects. Other embodiments are also disclosed.
Drugs covered by this patent
- Zavzpret (Zavegepant Hydrochloride) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.